Dr. Clay Siegall is a skilled biotechnology professional who understands a lot about the development of cancer therapies. He has worked for the government and the private sector as a researcher for decades and has managed to make significant contributions that have improved the pharmaceuticals industry. Siegall has spent the past one decade serving Seattle Genetics, which is a leading biotechnology-based company that he co-founded in 1998. He created the firm to develop better cancer cures since chemotherapies have side effects such as loss of hair to the patients.
Seattle Genetics has grown in the last two decades and is currently served by many scientists who have been working to establish the best cure for cancer. The organization has managed to secure approval of the FDA for various drugs that it has developed. It was the first firm ever to create the antibody drug conjugates technology that has been used in making great drugs. ADCs do not have adverse side effects on the human body like chemotherapy. The company generates money from licensing various pharmaceutical companies to use its ADC technology, internal manufacturing of drugs, and the income that it gets from different production partners. Clay believes that the Seattle Genetics’ workforce has played a significant role in making the company successful despite challenges that are faced in developing the drugs.
Clay Siegall has displayed excellent management skills for the past two decades that he has served as the CEO and chairperson of Seattle Genetics. The company has created various targeted cancer treatments, and it is still striving to improve the cures. It has worked with leading pharmaceuticals manufacturers such as Takeda, Genentech, and Bayer to ensure that its drugs reach the international market.
The academic credentials that Clay holds have enabled him to reach great heights in his career. He is a graduate of the prestigious George Washington University where he got his Ph.D. in genetics. The experience that Siegall has gained in the industry has enabled him to be appointed to serve as a board member in companies such as BioPharmaceuticals, Mirna Therapeutics, and Ultragenyx. Dr. Clay Siegall has 15 patents for various products that he has developed in his research career.